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The treatment of patients with chronic myelomonocytic leukemia (CMML) with transplant has not been
optimized. We retrospectively reviewed the data for 83 consecutive patients with CMML (47 with CMML-1/2
and 36 with CMML progressed to acute myeloid leukemia) who received an allogeneic stem cell transplant
(allo-SCT) at our institution between April 1991 and December 2013 to identify factors associated with
improved survival and determine whether treatment with hypomethylating agents before transplant im-
proves progression-free survival (PFS). The median age of the cohort was 57 years. Seventy-eight patients
received induction treatment before transplant, with 37 receiving hypomethylating agents and 41 receiving
cytotoxic chemotherapy. Patients treated with a hypomethylating agent had a signiﬁcantly lower cumulative
incidence of relapse at 3 years post-transplant (22%) than those treated with other agents (35%; P ¼ .03),
whereas treatment-related mortality at 1 year post-transplant did not signiﬁcantly differ between the groups
(27% and 30%, respectively; P ¼ .84). The lower relapse rate resulted in a signiﬁcantly higher 3-year PFS rate in
patients treated with a hypomethylating agent (43%) than in those treated with other agents (27%; P ¼ .04).
Our data support the use of hypomethylating agents before allo-SCT for patients with CMML to achieve
morphologic remission and improve PFS of these patients. Future studies are needed to conﬁrm these
ﬁndings.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION 2008 World Health Organization (WHO) classiﬁcation [1],
Chronic myelomonocytic leukemia (CMML) is a clonal
hematopoietic stem cell disorder characterized by peripheral
blood monocytosis and features of both a myeloproliferative
neoplasm and a myelodysplastic syndrome. According to thedgments on page 52.
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ty for Blood and Marrow Transplantation.CMML belongs to a category of mixed myeloproliferative/
myelodysplastic neoplasms and has 2 subtypes, CMML-1 and
CMML-2, depending on the number of blasts and promon-
ocytes present in the bone marrow and peripheral blood. To
date, there is no consensus on the optimal therapy for CMML
because of the heterogeneity of the disease. Treatment mo-
dalities for CMML include supportive care, hypomethylating
agents, cytotoxic chemotherapy, and allogeneic hematopoi-
etic stem cell transplantation (allo-SCT), which is the only
curative treatment modality for patients with CMML [2-9].
However, allo-SCT for this disease has been associated with
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and, in general, worse outcomes than for other myelopro-
liferative neoplasms [10]. Data regarding allo-SCT outcomes
in patients with CMML are currently limited to small retro-
spective series, and no prospective studies have been per-
formed for CMML patients because of the relatively low
number of patients with CMML treated with allogeneic
transplantation. Moreover, timing of allo-SCT and beneﬁt of
induction therapy, in particular treatment with a hypo-
methylating agent before transplant, has not been studied.
We therefore performed a retrospective analysis in a larger
number of CMML patients who underwent allogeneic
transplantation to identify factors associated with improved
outcomes and to determine whether treatment with hypo-
methylating agents before transplantation improves survival
in these patients.
METHODS
Patients
Eighty-three consecutive patients age 18 years or older with a diagnosis
of CMML conﬁrmed at The University of Texas MD Anderson Cancer Center
(UTMDACC) who underwent allo-SCT between April 1991 and December
2013 were identiﬁed through review of the institution’s medical records and
included in this analysis. Histologic subtypes at the time of diagnosis were
classiﬁed according to the 2008 WHO deﬁnitions [1]. Forty-seven patients
had CMML-1 or CMML-2 (CMML-1/2) (n ¼ 40 CMML-1 and n ¼ 7 CMML-2),
and 36 patients had CMML that had progressed to secondary acute myeloid
leukemia (CMML/AML). CMML-speciﬁc cytogenetic risk levels were deter-
mined at diagnosis according to the classiﬁcation system described by Such
et al. [11].
All patients provided written informed consent for transplant in
accordance with the Declaration of Helsinki. The Institutional Review Board
of UTMDACC approved the treatment protocols and this retrospective study.
Treatment before Transplantation and Transplant Procedures
We assessed the use of pretransplant treatments and the agents used for
those treatments on the basis of data extracted from the medical records.
Pretransplant induction therapies were various, mostly either 1 to 2 courses
of conventional chemotherapy (idarubicin plus cytarabine, referred to as the
7 þ 3 regimen [12], or idarubicin plus clofarabine plus cytarabine, known as
the CIA regimen [13]) or at least 3 courses of hypomethylating agents (5-
azacytidine or decitabine). The choice and dose of the pretransplant treat-
ments were based on the treating physician’s decision, disease status at
diagnosis, and the patient’s performance status. Patients who received hy-
droxyurea, supportive care alone, or less than 3 cycles of hypomethylating
agents before transplant were considered as having no induction therapy.
Responses to induction therapy were evaluated according to the Inter-
national Working Group response criteria before transplant [14]. All donors
and recipients had high-resolution molecular typing of HLA class I and II
antigens. Donor types were deﬁned according to previously described
criteria [15]. Conditioning regimens varied; most patients received either
ﬂudarabine in combination with busulfan or ﬂudarabine combined with
melphalan. The impact of conditioning regimens on outcomes was analyzed
by their dose intensity using the Center for International Blood and Marrow
Transplant Research criteria for myeloablative and reduced-intensity con-
ditioning regimens [16]. Graft-versus-host disease (GVHD) prophylaxis
consisted of tacrolimus .015 to .03 mg/kg (starting on day 2) and metho-
trexate of 5 mg/m2 on days þ1, þ3, and þ6. Patients who received trans-
plantations from matched unrelated or mismatched donors received an
additional dose of methotrexate of 5 mg/m2 on day þ11 and 1 mg/kg of
rabbit antithymocyte globulin i.v. on days 2 and 1 before allo-SCT. Acute
GVHD (aGVHD) and chronic GVHD (cGVHD) were graded according to
previously reported consensus criteria [17,18].
Endpoint Deﬁnitions and Statistical Analyses
We analyzed the impact of disease and transplant characteristics on the
outcomes of transplant, including the characteristics of age, Karnofsky
performance status, the 2008 WHO histologic subtype, bone marrow blast
count immediately before transplant, cytogenetics at diagnosis, the use of
hypomethylating agents before transplant, remission status before trans-
plant, year of transplant, conditioning intensity, donor type, and develop-
ment of aGVHD and cGVHD. The primary endpoint was progression-free
survival (PFS), and secondary endpoints were overall survival (OS), TRM,
relapse incidence through last follow-up, and incidences of aGVHD and
cGVHD. All outcomes were measured from the time of allo-SCT.PFS was deﬁned as the time until disease relapse or death from any
cause; data for patients who were alive without relapse were censored at
the date of last contact. OS was deﬁned as the time until death from any
cause; surviving patients were censored at the date of last contact. Relapse
was deﬁned as the recurrence of disease according to the 2008 WHO
criteria [1]. TRM was deﬁned as death related to allo-SCT during contin-
uous complete remission. OS and PFS were calculated using the Kaplan-
Meier method. Univariate comparisons of all endpoints were done using
the log-rank test. The cumulative incidence function with the competing
risks method was used to estimate the endpoints of relapse, TRM, aGVHD,
and cGVHD. A Cox proportional hazards model [19] or the Fine and Gray
method [20] for competing hazards was used for multivariate regression.
Variables were included in the multivariate model if they were concep-
tually important (ie, if they approached P < .1) or attained statistical sig-
niﬁcance in the univariate regression model. A P < .05 was considered for
statistical signiﬁcance. Analyses were performed using the Stata statistics
program (version 13; StataCorp, College Station, TX).
RESULTS
Patient and Transplant Characteristics
Median patient age was 57 years (range, 18 to 78). Thirty-
three patients (39.7%) were older than 60 years. CMML-
speciﬁc cytogenetic risk levels at diagnosis according to the
classiﬁcation system as described by Such et al. [11] were
low, intermediate, and high risk in 46 (55.4%), 19 (22.9%), and
18 (21.6%) patients, respectively. There were no signiﬁcant
differences in characteristics between patients with CMML-
1/2 and those with CMML/AML, as shown in Table 1. Four-
teen patients (30%) with CMML-1/2 and 10 patients (28%)
with CMML/AML achieved a complete remission before
transplant (P ¼ .87).
Seventy-eight patients (94%) received induction treat-
ment before transplant, 37 patients (44.6%) with a hypo-
methylating agent (either 5-azacytidine or decitabine) for at
least 3 courses (median, 6 courses) and 41 patients (49.3%)
with AML-type induction chemotherapy. The other 5 pa-
tients received standard supportive care and/or hydroxyurea
before transplant. Patient and transplant characteristics did
not signiﬁcantly differ between patients treated with hypo-
methylating agents and patients treated with conventional
chemotherapy (without hypomethylating agents) or given
supportive care alone; however, more patients who did not
receive hypomethylating agents underwent allo-SCT before
the year 2005 (67% versus 0%; P< .001) (Table 2). A complete
remission or marrow complete remission before transplant
was seen in 41% of patients (n ¼ 15) treated with hypo-
methylating agents and 20% of patients (n ¼ 9) treated with
other agents (P ¼ .12).
Themedian time fromdiagnosis to allo-SCTwas 8months
(range, 3 to 86). There was no difference in median time to
transplant in patients who received induction therapy with
hypomethylating agents and those who received conven-
tional chemotherapy or supportive care (6 versus 9 months;
P ¼ .32). However, patients with CMML/AML had a shorter
duration from diagnosis to transplant compared with pa-
tients with CMML-1/2 (4 versus 11 months; P ¼ .02). Thirty,
47, and 6 patients received transplants frommatched related
donors (MRD), matched unrelated donors, and mismatched
related or unrelated donors, respectively. The sources of
hematopoietic stem cells were peripheral blood for 48 pa-
tients (57.8%) and bone marrow for 35 patients (42.2%).
Sixty-four patients (77.1%) received myeloablative condi-
tioning and 19 patients (22.9%) reduced-intensity condi-
tioning regimens.
Transplant Outcomes by CMML Category
At the last follow-up, 29 patients were alive (18 of these
patients received induction treatment with hypomethylating
Table 1
Patient and Transplant Characteristics by CMML Category
Characteristic All patients (n ¼ 83) CMML-1/2 (n ¼ 47) CMML/AML (n ¼ 36) P
n Percent
or Range
n Percent
or Range
n Percent
or Range
Median age, yr 57 18-78 58 18-74 56 18-78 .75
Age >60 yr 33 39.8 21 46.6 12 33.3 .52
Median blast percentage at transplant 3 0-83 3 0-17 4 0-83 .43
Gender: male 58 70 34 72 24 66 .84
Complex cytogenetics (3 abnormalities) 8 9.6 3 6.3 5 13.9 .21
CMML-speciﬁc cytogenetics .12
Low 46 55.4 30 63.8 16 44.4
Intermediate 19 22.9 9 19 10 27.8
High 18 21.7 8 17 10 27.8
MDAPS .08
Low 5 5 4 8.5 1 2.8
Intermediate-1 11 13.3 6 12.7 5 13.9
Intermediate-2 7 8.4 4 8.5 3 8.3
High 3 3.6 2 4.2 1 2.8
Prior allo-SCT 5 6 3 6.3 2 5.6 .97
Prior ASCT 4 4.8 3 6.3 1 2.8 .55
Hypomethylating treatment 37 44.6 23 48.9 14 38.9 .25
Response before transplant .08
CR/mCR 24 28.9 18 38.3 6 16.7
Karnofsky 90 51 70.8 29 61.7 22 66.7 .36
Conditioning .13
MAC 64 77 36 76.5 28 77.7
Stem cell source .44
PB 48 57.8 27 57.4 21 58.3
BM 35 42.2 20 42.5 15 41.7
Donor .74
MRD 30 36.1 17 36.1 13 36.1
MUD 47 56.6 28 59.5 19 52.8
MMD 6 7.2 2 4.2 4 11.1
Engraftment 75 90.4 42 89.3 33 91.7 .69
Median time to ANC engraftment, day 13 8-46 13 9-30 13 8-46 1.0
Median time to platelet engraftment, day 15 8-90 16 8-90 14 8-78 .83
Chimerism .23
Donor 44 53 26 55.3 18 50
Mixed 29 34.9 16 34 13 36.1
Autologous 1 1.2 0 0 1 2.8
Final response .88
CCR/CR 74 89.2 33 82.5 34 94.5
MDAPS indicates MD Anderson Prognostic Scoring System; ASCT, autologous stem cell transplantation; CR/mCR, complete remission/marrow complete
remission; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow; MUD, matched unrelated donor; MMD, mismatched related and unre-
lated donor; ANC, absolute neutrophil count; CCR, complete cytogenetic remission.
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The transplant outcomes are summarized in Table 3. The
cumulative incidence of engraftment at day 30 post-
transplant for the entire group was 98%. The median time
to neutrophil and platelet engraftment was 13 days and
15 days, respectively.
The cumulative incidences of TRM at day 100 and at 1 year
post-transplant for the entire cohort were 25% and 31%,
respectively. Causes of early death within 100 days were
infection (64%), organ failure (24%), and severe aGVHD (12%).
TRM rates did not differ signiﬁcantly between the CMML
subtypes;patientswithCMML-1/2and thosewithCMML/AML
had 1-year TRM rates of 29% and 35%, respectively (P ¼ .76).
The cumulative incidence of aGVHD (all grades) at
100 days post-transplant was 36%, whereas for grades II to IV
aGVHD was only 12%. Patients with CMML-1/2 and those
with CMML/AML developed grades II to IV aGVHD at
100 days post-transplant at rates of 13% and 8%, respectively
(P ¼ .37). The overall cumulative incidence of cGVHD at
1 year after transplant was 38%, higher in patients with
CMML-1/2 than in those with CMML/AML (43% versus 35%;
P ¼ .02). The cumulative incidences of extensive cGVHD at
1 year post-transplant was 24% overall, 31% for patients with
CMML-1/2, and 16% for CMML/AML (P ¼ .04).The cumulative incidence of disease relapse at 3 years
post-transplant for the entire cohort was 33%, with no dif-
ferences between the 2 groups: 35% and 27% for CMML-1/2
and CMML/AML, respectively (P ¼ .39). The 3-year PFS rate
was 34% for the entire cohort, 35% for patients with CMML-1/
2, and 27% for patients with CMML/AML (P ¼ .31; Figure 1A).
The 3-year OS rates for the CMML-1/2 and CMML/AML
groups were 36% and 32%, respectively (P ¼ .62).
Transplant Outcomes by Treatment with
Hypomethylating Agents
Successful engraftment was seen in 33 patients treated
with hypomethylating agents (89%) and in 42 patients
treated with other agents (91%; P .13). At day 100 post-
transplant, 30 patients treated with hypomethylating
agents (81%) and 44 patients treated with other treatments
(96%) achieved complete remission or complete cytogenetic
remission (P ¼ .21).
Patients treated with a hypomethylating agent had a
signiﬁcantly lower cumulative incidence of relapse at 3 years
post-transplant (22%) than those treated with other agents
(35%; P¼ .03), whereas TRM at 1 year post-transplant did not
signiﬁcantly differ between the groups (27% and 30%,
respectively; P ¼ .84). The lower relapse rate resulted in a
Table 2
Patient and Transplant Characteristics by Treatment with Hypomethylating
Agent
Characteristic Hypomethylating Treatment P
Yes (n ¼ 37) No (n ¼ 46)
n Percent
or Range
n Percent
or Range
Median age, yr 60 18-78 55.5 17-75 .43
Age >60 yr 18 48.6 15 32.6 .17
Median ANC engraftment,
day
12 11-30 13 8-56 .54
Median platelet
engraftment, day
14 9-44 16 8-90 .63
Median percentage of blast
at the time of transplant
3 0-83 4 0-53 .49
Gender: male 26 68 32 70 1.00
Histology at diagnosis .60
CMML-1/2 23 62 24 52
CMML/AML 14 37.8 22 47.8
CR/mCR before transplant 15 40.5 9 19.5 .12
Complex cytogenetics 3 8.1 5 10.9 .72
CMML-speciﬁc cytogenetics .72
Low 21 56.8 25 54.3
Intermediate 7 18.9 12 26.1
High 9 24.3 9 19.6
Prior allo-SCT 2 5.4 3 6.5 1.00
Prior ASCT 1 2.7 3 6.5 .62
Karnofsky 90 23 67.6 28 73.7 .61
Transplant before 2005 0 0 30 67 .001
Conditioning
MAC 30 81 34 73.9 .60
Stem cell source .09
PB 24 64.9 24 52.2
BM 35 35.2 22 47.8
Donor .94
MRD 14 37.8 16 34.8
MUD 20 54.1 27 58.7
MMD 3 8.1 3 6.5
Engraftment 33 89.2 42 91.3 .13
Chimerism .11
Donor 16 43.2 28 60.9
Mixed 17 45.9 12 26.1
Autologous 0 0 1 2.2
Final response .21
CCR/CR 30 81.1 44 95.6
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hypomethylating agent (43%) than in those who received
other treatment (27%; P ¼ .04) (Figure 1B). The beneﬁts of
hypomethylating agent treatment on relapse and PFS were
seen only in patients who achieved a complete remission
before transplant, whereas patients who were not in remis-
sion had similar relapse rates and survival. However, therapy
with hypomethylating agents before transplant did not
signiﬁcantly inﬂuence the 3-year OS rate (45% in thoseTable 3
Transplant Outcomes by CMML Category and Treatment with Hypomethylating Ag
Outcome Total (%) CMML-1/2 (%) CMML/AML (%)
aGVHD, all grades 35.9 33.2 38.1
aGVHD grades II-IV 11.7 13.1 8.3
aGVHD grades III-IV 5.8 9.2 4.7
cGVHD 37.5 42.2 35
Extensive cGVHD 23.9 30.6 15.6
100-day TRM 24.7 20.8 25.2
1-year TRM 31.1 29 35.3
3-year CI of relapse 33.3 35.4 26.7
3-year PFS 33.9 35 27.4
3-year OS 35.2 36.1 32.2treated with hypomethylating agents and 39% in those
treated with other agents; P ¼ .22).Factors Predicting Transplant Outcomes
In the univariate analysis for PFS, factors associated with
longer PFS were less than 5% bone marrow blasts before
transplant (P¼ .02), treatment with a hypomethylating agent
(P ¼ .04), a transplant from an MRD (P ¼ .002), and the
development of cGVHD (P < .001). Conversely, the develop-
ment of grades II to IV aGVHD was associated with shorter
PFS (P ¼ .02). All these factors remained signiﬁcant in
multivariate regression analysis. The independent prognostic
factors for PFS were a blast count of less than 5% immediately
before transplant (hazard ratio [HR], .36; 95% conﬁdence
interval [CI], .14 to .78; P ¼ .04), treatment with a hypo-
methylating agent (HR, .44; 95% CI, .23 to .86; P ¼ .03), a
transplant from an MRD (HR, .41; 95% CI, .22 to .94; P ¼ .03),
development of grades II to IV aGVHD (HR, 2.7; 95% CI,1.27 to
5.77; P ¼ .01), and development of cGVHD (HR, .15; 95% CI,
.05 to .45; P ¼ .001) (Figure 2). Also, in the multivariate
analysis using remission status before transplant together
with hypomethylating agent treatment, we found that both
factors were an independent predictor for longer PFS.
In the univariate analysis for disease relapse, a blast per-
centage of less than 5% (P ¼ .03), treatment with a hypo-
methylating agent (P ¼ .03), transplant from an MRD
(P ¼ .02), and development of cGVHD (P ¼ .02) were each
associated with a lower relapse incidence. All these factors
also were independent predictors of lower relapse incidence
in multivariate analysis, with HRs of .28 (95% CI, .11 to 0.49;
P ¼ .02) for less than 5% bone marrow blasts at the time of
transplant, .67 (95% CI, .43 to .88; P ¼ .03) for the use of
hypomethylating agents, .87 (95% CI, .66 to .95; P ¼ .04) for
using an MRD, and .22 (95% CI, .13 to .39; P ¼ .02) for cGVHD.
In univariate analysis for TRM, the development of grades
II to IV aGVHD (P¼ .005) and agemore 60 years (P¼ .04) each
predicted higher TRM. However, only grades II to IV aGVHD
was a signiﬁcant predictor of higher TRM in multivariate
analysis (HR, 3.8; 95% CI, 2.13 to 6.22; P ¼ .03). Age, CMML
cytogenetic risk category, conditioning intensity, and year of
transplant did not predict transplant outcomes.DISCUSSION
In this report, which we believe is the largest retro-
spective single-institution analysis looking at the effects of
pretransplant therapies of adult CMML patients treated with
allo-SCT performed to date, we also have identiﬁed impor-
tant factors that inﬂuence transplant outcomes. We
conclude that (1) disease burden appreciated by theent
P Hypomethylating
treatment (%)
No Hypomethylating
treatment (%)
P
.74 28.2 35.8 .05
.37 12.8 11.3 .72
.65 8.4 3.7 .36
.02 35 38.2 .64
.04 26.7 19.2 .36
.78 18.1 21.2 .55
.76 27.4 29.8 .84
.39 22.4 34.9 .03
.31 43.2 27.4 .04
.62 45.2 38.7 .22
Figure 1. PFS by CMML category (A) and treatment with hypomethylating
agent before transplant (B).
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determines prognosis after transplant, (2) allo-SCT can
overcome the poor prognosis associated with high-risk
CMML-speciﬁc cytogenetics, and (3) treatment with a
hypomethylating agent before transplant decreases relapse
rate and improves PFS.
The prognostic signiﬁcance of bone marrow blast per-
centage in patients with CMML has been previously evalu-
ated in several studies [21-23] and has been incorporated in
various prognostic models of CMML [24-26]. Investigators
from UTMDACC developed the MD Anderson Prognostic
Scoring System for CMML based on survival analysis of 213
patients with CMML. This scoring system included 4 baseline
clinical characteristics, including the bone marrow blast
count at diagnosis, and was validated in a cohort of 250 pa-
tients with CMML from the same institution [24,25]. How-
ever, for patients with CMML undergoing allo-SCT, the
disease burden at the time of transplant seems to have a
greater prognostic impact than the disease burden at diag-
nosis. Krishnamurthy et al. [4] reported 3-year disease-free
survival rates of 47% for patients who had less than 5%
bone marrow blasts at transplant versus 20% for those with
more than or equal to 5% blasts at the time of transplant,
whereas Kröger et al. [5] found that the 2-year disease-free
survival was 33% in patients with less than 10% marrow
blasts compared with 12% for those with more than or equal
to 10% marrow blasts at the time of transplant. Even thoughthese ﬁndings were not statistically signiﬁcant in either
study, probably because of the small numbers of patients,
both studies suggested a prognostic signiﬁcance of bone
marrow blast percentage immediately before transplant. In
the present study, we have clearly shown that patients with
less than 5% bone marrow blasts at transplant had a lower
risk of relapse and better PFS than those with higher bone
marrow blast count. However, we did not identify a signiﬁ-
cant difference in transplant outcomes between patients
with CMML-1/2 and those with CMML/AML, stratiﬁed on the
basis of blast count at diagnosis. Taken together, these ﬁnd-
ings suggest that the disease burden appreciated by the bone
marrow blast percentage at the time of transplant rather
than at diagnosis is an important prognostic factor for
transplant outcomes and that patients with CMML should be
treated with induction therapy to achieve at least morpho-
logic remission before transplant to improve survival after
transplant.
Another important ﬁnding was that the cytogenetic risk
did not signiﬁcantly affect transplant outcomes in patients
with CMML, in contrasts with previous ﬁndings. Unlike for
other myelodysplastic syndromes, in which chromosomal
abnormalities strongly affect treatment outcomes, the
prognostic signiﬁcance of chromosomal abnormalities in
CMML remains unclear. Moreover, no speciﬁc cytogenetic
alterations have been associated with CMML, although
recurring chromosomal abnormalities have been reported
in this disease [25,27,28]. The Spanish MDS Cooperative
Group investigated the prognostic signiﬁcance of chromo-
somal abnormalities in patients with CMML and found that
patients with low risk (normal karyotype or loss of Y
chromosome as a single anomaly), intermediate risk (all
other abnormalities except those considered high risk), and
high risk (presence of trisomy 8, abnormalities of chromo-
some 7, or complex karyotype) had 5-year OS rates of 35%,
26%, and 4%, respectively (P ¼ .001). However, these results
reﬂected the natural history of this disease, because no
patient in this study was treated with hypomethylating
agents, and patients undergoing allo-SCT (n ¼ 4) or inten-
sive AML-type chemotherapy (n ¼ 23) were censored from
the survival analysis at the time of transplant or at the start
of chemotherapy, respectively [11].
Although transplant outcomes according to the Interna-
tional Prognostic Scoring System (IPSS) or the Revised IPSS
could not be analyzed in the present study (because of lim-
itations in the data available) and although these prognostic
scoring systems were not developed for CMML patients, a
few studies have suggested that high cytogenetic risk ac-
cording to the IPSS is associated with increased relapse rate
and worse survival post-transplant in patients with CMML
[5,9]. In a study from the Fred Hutchinson Cancer Research
Center (which included both pediatric and adult patients),
high cytogenetic risk according to the IPSS was associated
with increased mortality rate and reduced relapse-free sur-
vival in patients with CMML treated with allo-SCT [9]. Our
study showed that patients with low-risk, intermediate-risk,
and high-risk cytogenetics according to the risk classiﬁcation
system used by The SpanishMDS Cooperative Group [11] had
similar transplant outcomes; therefore, these results suggest
that transplantation can overcome the poor prognosis of
CMML with high-risk cytogenetics.
Treatment with hypomethylating agents, such as decita-
bine and 5-azacytidine, have proven efﬁcacy not only for
patients with myelodysplastic syndromes but also for those
with CMML. Several completed phase II studies, investigating
Figure 2. Forest plot representation of factors included in the multivariate analysis for PFS. RIC indicates reduced-intensity conditioning.
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CMML, showed overall response rates ranging from 25% to
70% and median OS times ranging from 12 to 37 months [29-
35]. However, the beneﬁt of treatment with a hypo-
methylating agent before transplant in patients with CMML
has not been addressed. Our study is the ﬁrst to associate the
treatment with hypomethylating agents with lower relapse
rates and superior PFS after transplant, when compared with
conventional induction chemotherapy or supportive care
alone. Treatment with hypomethylating agents remained an
independent prognostic factor for lower relapse and better
PFS in multivariate analysis. The mechanism by which these
agents reduce the relapse rate post-transplant remains un-
clear; however, a better suppression of malignant clones and
minimization of residual disease in the bone marrow before
transplant is possible. Even though remission rates before
transplant in the 2 groups was not different (41% in hypo-
methylating group versus 20% in other patients; P ¼ .12), this
may be due to a small number of patients in both groups,
which is the main limitation of this study. Randomized
prospective studies are needed to clarify this issue.
Our data suggest that treatment with hypomethylating
agents should continue for at least 3 courses with the goal of
achieving morphologic remission (<5% bone marrow blasts)
before transplant. This amount of time would be enough for
the transplant physician to identify a donor and prepare for
transplant. Thus, we suggest that transplant is performed
soon after the patient has achieved morphologic remission,
because a longer period of treatment may increase the risk of
disease progression and compromise transplant outcomes.
This is the largest single-institution analysis in adult pa-
tients undergoing allo-SCT for CMML and the ﬁrst to show
that treatment with hypomethylating agents before trans-
plant may impact survival after transplant. However, these
data should be interpreted with caution because they are
nonrandomized, from a single center, and retrospective in
nature with a limited number of patients. Analysis of a larger
number of patients as well as controlled studies are needed
to conﬁrm these ﬁndings.ACKNOWLEDGMENTS
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